biolitec^® continues to break boundaries with the addition of a new treatment in cardiac electrophysiology called CALA – Cardiac Arrhythmia Laser Ablation. This treatment is indicated for Ventricular Tachycardia and Supraventricular Tachyarrhythmias such as Atrial Fibrillation, Atrial Tachycardia, Atrial Flutter, Atrioventricular Nodal Re-entrant Tachycardia (AVNRT), Accessory Atrioventricular Pathways (AP) and Inappropriate Sinus Tachycardia.

The CALA treatment is made possible through the specially designed CALA fiber, used with the state-of-the-art LEONARDO^® FPS 1064 laser and the LEONARDO^® FLOW pump. The CALA fiber ablates the disturbing conduction paths inside the heart. The therapeutic laser ablation causes electrical inactivation of the tissue in a controlled manner. The laser beam from the CALA fiber accompanied by irrigation creates a transmural lesion.

Atrial fibrillation is one of the most common rhythm disorders in Europe. Around 14-17 million people may suffer in Europe from AF by 2030. Atrial fibrillation is a supraventricular tachyarrhythmia that is triggered by additional irregular electrical impulses (extra beats from the atrium chamber of the heart). Patients suffering from atrial fibrillation have poor quality of life, increased risk of strokes and heart failure. The number of patients is rapidly rising due to an aging population and increasing lifestyle risk factors (such as obesity, alcohol consumption, smoking, stress and limited activity).

Medicinal treatment is the initial approach, but catheter ablation treatment provides better quality of life and freedom from AF recurrence. The catheter ablation treatment is done by cardiac electrophysiologists inside catheterization labs equipped with EP recording and mapping systems.